SELLAS Life Sciences Group (SLS) said Tuesday the US Food and Drug Administration has granted its Galinpeimut-S immunotherapy targeting Wilms Tumor-1 for treating pediatric acute myeloid leukemia Rare Pediatric Disease Designation.
The designation could potentially qualify SELLAS for a "Priority Review Voucher," if the therapy is approved for pediatric AML in the future, the company said.
Shares of the company rose 1.6% in early Tuesday trading.
Price: 1.27, Change: +0.02, Percent Change: +1.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。